News

The trial is the first with an SGLT2 inhibitor investigating the treatment of heart failure in patients with reduced ejection fraction, with and without type II diabetes.

The industry body hopes that the proceeding Government will “shape one of our country’s most valuable assets: an incredible pharmaceutical industry that employs tens of thousands and invests billions in research.”

Isturisa, Mayzent and Polivy were among the recommendations.

The study team will review how current health and social care systems work.

The company has also submitted a marketing authorisation application for the drug to the European Medicines Agency.

The therapy, a once-daily oral medicine, was initially approved in the US in May 2019 under the name Qternmet XR.

The organisation updates its MS Guideline to state that Sativex should be offered to treat spasticity in people with the disorder.

The study is the sixth Phase III trial of the drug’s programme.

Only one drug has been approved for the indication in the lat 60 years, GlaxoSmithKline’s Benlysta (belimumab), which was also the first-ever biologic treatment for the disease.

More than half of the public are not aware the condition may be preventable, and just under half are unaware of the steps that can be taken to prevent or delay the development of the condition.

The study was the first randomised trial to test the abdominal stitch in this group of women.

42.2% of non-radiographic axial spondyloarthritis patients showed a significant and clinically meaningful reduction in disease activity.